Moore v. GlaxoSmithKline Consumer Healthcare Holdings (US) LLC

CourtDistrict Court, N.D. California
DecidedJanuary 30, 2024
Docket4:20-cv-09077
StatusUnknown

This text of Moore v. GlaxoSmithKline Consumer Healthcare Holdings (US) LLC (Moore v. GlaxoSmithKline Consumer Healthcare Holdings (US) LLC) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Moore v. GlaxoSmithKline Consumer Healthcare Holdings (US) LLC, (N.D. Cal. 2024).

Opinion

1 2 3 UNITED STATES DISTRICT COURT 4 NORTHERN DISTRICT OF CALIFORNIA 5 LISA M. MOORE individually and on Case No: 4:20-cv-09077-JSW 6 behalf of all others similarly situated, ORDER GRANTING MOTION TO 7 CERTIFY CLASS AND GRANTING Plaintiff, 8 v. AND DENYING MOTIONS TO EXCLUDE

9 GLAXOSMITHKLINE CONSUMER Re: Dkt. Nos. 63, 81, 82, 94 10 HEALTHCARE HOLDINGS (US) LLC and

PFIZER INC., 11 Defendants. 12 13 Now before the Court for consideration are Plaintiff’s motion for class certification; 14 Plaintiff’s motions to exclude the expert testimony of Dr. Steven Dentali; and Defendants’ 15 motions to exclude the expert testimony of Dr. Michael Dennis, Mr. Colin B. Weir, and Dr. Anton 16 Toutov. The Court has considered the parties’ papers, relevant legal authority, and the record in 17 this case, and the Court finds the motions suitable for disposition without oral argument. See N.D. 18 Civ. L.R. 7-1(b). For the reasons set forth below, the Court HEREBY GRANTS IN PART AND 19 DENIES IN PART Plaintiff’s class certification motion insofar as the motion to certify under 20 Rule 23(b)(2) is GRANTED, while the motion to certify under Rule 23(b)(3) is DENIED. The 21 Court also GRANTS Plaintiff’s motion to exclude the expert testimony of Dr. Steven Dentali and 22 Defendants’ motion to exclude the expert testimony of Dr. Anton Toutov, and DENIES 23 Defendants’ motions to exclude the expert testimony of Dr. Michael Dennis and Mr. Colin B. 24 Weir. 25 BACKGROUND 26 Plaintiff Lisa Moore (“Plaintiff”) brings this putative consumer class action on behalf of 27 herself and all residents of California who purchased certain ChapStick products within four years 1 Healthcare Holdings (US) LLC falsely label certain of their ChapStick products with the claims 2 “100% Natural,” “Natural,” “Naturally Sourced Ingredients,” and “100% Naturally Sourced 3 Ingredients” (collectively, the “Challenged Statements”). (Dkt. No. 63-1 at 1–2 (“MPA”).) 4 Plaintiff alleges these representations are false because the challenged ChapStick products contain 5 non-natural, synthetic, artificial, and/or highly processed ingredients. (Id.) 6 Plaintiff challenges six ChapStick products: (1) ChapStick 100% Natural Lip Butter, which 7 comes in four scents; (2) ChapStick Total Hydration 100% Natural Lip Balm, which comes in four 8 scents; (3) ChapStick Total Hydration Essential Oils Lip Balm, which comes in five scented- 9 variations; (4) ChapStick Total Hydration Moisture + Tint Lip Balm, which comes in eight shades; 10 (5) Total Hydration Moisture + Tint SPF 15 Lip Balm, which comes in three scents; and (6) 11 ChapStick Total Hydration Natural Lip Scrub, which comes in two scents (collectively, the 12 “Products”). (Dkt. No. 22 ¶ 2 (FAC).) Plaintiff alleges that the Products contain ingredients that 13 are non-natural, synthetic, artificial, and/or highly processed, and she identifies eight such 14 ingredients that are allegedly present in the Products: (1) caprylic/capric triglycerides, (2) 15 capryloyl glycerin/sebacic acid copolymer; (3) carmine, (4) hydrogenated soybean oil, (5) 16 octyldodecanol, (6) tocopherol acetate, (7) polyhydroxystearic acid, (8) jojoba esters. (MPA 8.) 17 Plaintiff, a resident of California, alleges that she routinely purchased two scent variations 18 of ChapStick Total Hydration 100% Natural Lip Balm and one scent variation of the ChapStick 19 Total Hydration Essential Oils Lip Balm at CVS and Walgreens stores in or around San Francisco. 20 (FAC ¶ 6.) Plaintiff alleges that she relied on the Challenged Statements on those labels and 21 would not have purchased the products if she knew that they contained non-natural ingredients. 22 (Id.) Plaintiff further alleges that she continues to desire to purchase the Products if they did not 23 contain any non-natural ingredients but is unable to rely on the truth of the Challenged Statements 24 and does not know the meaning of the Products’ ingredients. (Id. ¶¶ 6–7.) Based on these 25 allegations, Plaintiff brings causes of action for violations of: (1) California’s Unfair Competition 26 Law, Business and Professions Code sections 17200, et seq. (“UCL”); (2) California’s False 27 Advertising Law, Business and Professions Code sections 17500, et seq. (“FAL”); and (3) 1 (“CLRA”). Plaintiff also brings causes of action for breach of express warranty and unjust 2 enrichment. 3 I. MOTIONS TO EXCLUDE 4 A. Applicable Legal Standard 5 Federal Rule of Evidence 702 permits opinion testimony by an expert as long as the expert 6 is qualified and his or her opinion is relevant and reliable. An expert witness may be qualified by 7 “knowledge, skill, experience, training, or education.” Fed. R. Evid. 702. “[I]n evaluating 8 challenged expert testimony in support of class certification, a district court should evaluate 9 admissibility under the standard set forth” in Daubert v. Merrell Dow Pharm., Inc., 509 U.S. 579, 10 589-90, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993). Grodzitsky v. Am. Honda Motor Co., 957 F.3d 11 979, 985 (9th Cir. 2020) (citation omitted). A court may exclude expert testimony submitted in 12 support of class certification if it does not comply with the standards set forth in Daubert. See id. 13 “Under Daubert, ‘the district court judge must ensure that all admitted expert testimony is 14 both relevant and reliable.’” Id. (quoting Wendell v. GlaxoSmithKline LLC, 858 F.3d 1227, 1232 15 (9th Cir. 2017)). “Scientific evidence is reliable if the principles and methodology used by an 16 expert are grounded in the methods of science.” Wendell, 858 F.3d at 1232 (citation and internal 17 quotation marks omitted). “The focus of the district court’s analysis must be solely on principles 18 and methodology, not on the conclusions that they generate,” and “the court's task is to analyze 19 not what the experts say, but what basis they have for saying it.” Id. (citations, alteration, and 20 internal quotation marks omitted). In conducting this analysis, the district court may consider 21 “whether the theory or technique employed by the expert is generally accepted in the scientific 22 community; whether it’s been subjected to peer review and publication; whether it can be and has 23 been tested; and whether the known or potential rate of error is acceptable.” Id. (citation omitted). 24 B. Defendants’ Motion to Exclude the Expert Report of Dr. Michael Dennis 25 Plaintiff offers the expert testimony of Dr. Michael Dennis, Ph.D., a survey researcher, for 26 a proposed consumer perception survey and proposed conjoint analysis. For the consumer 27 perception survey, Dr. Dennis proposes a method for conducting a market research study that can 1 members were misled as alleged by the Plaintiff. (Dkt. No. 63-3 ¶ 21 (“Dennis Report”).) For the 2 conjoint analysis, Dr. Dennis provides a proposed method for conducting a market research study 3 that can measure the market price premium attributable to the Challenged Statements. Id. 4 Defendants argue that Dr. Dennis’s survey deviates from accepted principles of survey 5 design for a variety of reasons, including its lack of sufficient controls and reliance on improper 6 closed-ended and leading questions. Defendants argue that Dr. Dennis’s conjoint analysis suffers 7 from the decision to combine various product lines into just four surveys, including language that 8 is not challenged in the survey, and failing to account for supply-side factors. Plaintiff disputes 9 these points and argues that any concerns regarding the survey go to weight, not admissibility.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)
Amchem Products, Inc. v. Windsor
521 U.S. 591 (Supreme Court, 1997)
Wolin v. Jaguar Land Rover North America, LLC
617 F.3d 1168 (Ninth Circuit, 2010)
Bateman v. American Multi-Cinema, Inc.
623 F.3d 708 (Ninth Circuit, 2010)
Wal-Mart Stores, Inc. v. Dukes
131 S. Ct. 2541 (Supreme Court, 2011)
Stearns v. Ticketmaster Corp.
655 F.3d 1013 (Ninth Circuit, 2011)
United States v. Alex G. Merklinger
16 F.3d 670 (Sixth Circuit, 1994)
Comcast Corp. v. Behrend
133 S. Ct. 1426 (Supreme Court, 2013)
Lynne Wang v. Chinese Daily News, Inc.
737 F.3d 538 (Ninth Circuit, 2013)
Van Asdale v. International Game Technology
577 F.3d 989 (Ninth Circuit, 2009)
Lozano v. AT & T Wireless Services, Inc.
504 F.3d 718 (Ninth Circuit, 2007)
In Re Vioxx Class Cases
180 Cal. App. 4th 116 (California Court of Appeal, 2009)
Lavie v. Procter & Gamble Co.
129 Cal. Rptr. 2d 486 (California Court of Appeal, 2003)
Pulaski & Middleman, LLC v. Google, Inc.
802 F.3d 979 (Ninth Circuit, 2015)
Stephen Wendell v. Glaxosmithkline LLC
858 F.3d 1227 (Ninth Circuit, 2017)
Tamara Moore v. Mars Petcare US, Inc.
966 F.3d 1007 (Ninth Circuit, 2020)

Cite This Page — Counsel Stack

Bluebook (online)
Moore v. GlaxoSmithKline Consumer Healthcare Holdings (US) LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/moore-v-glaxosmithkline-consumer-healthcare-holdings-us-llc-cand-2024.